<Disease><Name>NONALCOHOLIC FATTY LIVER DISEASE  [DD]</Name><Synonym>NAFLD</Synonym><OMIM><Number>---</Number><URL>http://omim.org/entry/---</URL></OMIM><Orphanet><Number>---</Number><URL>http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&amp;Expert=---</URL></Orphanet><Protein><Number /><URL /></Protein><ExPASy><Number>---</Number><URL>http://enzyme.expasy.org/EC/---</URL></ExPASy><Gene>---Detail information to gene locus by the National Center for Biotechnology Information NCBI:

MAJOR HISTOCOMPATIBILITY COMPLEX
</Gene><ICD /><Summary>Central obesity, dyslipidaemia, hyperglycaemia, and hypertension are typical features of metabolic syndrome that seem to hesitate often in type 2 diabetes, cardiovascular ;disease;, ;non-alcoholic fatty liver disease;, and many other clinical conditions [Mameli C 2017].;Non-alcoholic fatty liver disease (NAFLD) is considered to be the hepatic component of the metabolic syndrome and its prevalence is rapidly increasing due to its strong association with insulin resistance and obesity [Rodiriguez-Ramiro; et al. 2015;]</Summary><Symptoms><symtomp><id>1998</id><symptom>liver involvement or dysfunction</symptom><category>GASTROINTESTINAL SYSTEM</category></symtomp><symtomp><id>2372</id><symptom>obesity</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2506</id><symptom>onset, adolescent / adolescence</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2507</id><symptom>onset, childhood / childhood</symptom><category>GENERAL TOPICS</category></symtomp><symtomp><id>2505</id><symptom>onset, infancy / infancy</symptom><category>GENERAL TOPICS</category></symtomp></Symptoms><Metabolites><metabolite><id>1559</id><name>1-Methylhistidine</name><specimen>urine</specimen><value>normal/inc</value><min>2.40</min><max>28.40</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>1980</id><name>1-Methylhistidine</name><specimen>urine</specimen><value>normal/inc</value><min>0.00</min><max>380.00</max><unit>mol/mol creatinine</unit><age>Neonatal</age><method>NMR</method><comment /></metabolite><metabolite><id>1988</id><name>1-Methylhistidine</name><specimen>urine</specimen><value>normal/inc</value><min>2.40</min><max>28.40</max><unit>mmol/mol creatinine</unit><age>Adulthood</age><method>NMR</method><comment>The Human Urine Metabolome</comment></metabolite><metabolite><id>416</id><name>Transaminases (ASAT/ALAT)</name><specimen>serum</specimen><value>increased</value><min>10.00</min><max>30.00</max><unit>U/l</unit><age>child</age><method /><comment /></metabolite></Metabolites><Literatures><literature><id>3950</id><title>Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transport</title><author>Cobbina E,</author><journal>Drug Metab Rev</journal><year>2017</year><book /><volume>17</volume><number>0</number><pages>1-15</pages><co_aut>Akhlaghi F</co_aut></literature><literature><id>3951</id><title>Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease</title><author>Miyaaki H,</author><journal>Clin J Gastroenterol</journal><year>2017</year><book /><volume>10</volume><number>3</number><pages>201-207</pages><co_aut>Nakao K</co_aut></literature><literature><id>3952</id><title>Non-alcoholic fatty liver disease</title><author>Neuschwander-Tetri BA</author><journal>BMC Med</journal><year>2017</year><book /><volume>15</volume><number>1</number><pages>45</pages><co_aut /></literature><literature><id>3953</id><title>An update on the assessment and management of metabolic syndrome, a growing medical emergency in paediatric populations</title><author>Mameli C,</author><journal>Pharmacol Res</journal><year>2017</year><book /><volume>119</volume><number>0</number><pages>99-117</pages><co_aut>et al.</co_aut></literature><literature><id>7268</id><title>Urinary Metabolomics in Pediatric Obesity and NAFLD Identifies Metabolic Pathways/Metabolites Related to Dietary Habits and Gut-Liver Axis Perturbations</title><author>Troisi J,</author><journal>Nutrients</journal><year>2017</year><book /><volume>9</volume><number>5</number><pages>E485</pages><co_aut>et al.</co_aut></literature><literature><id>3954</id><title>Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions</title><author>Clemente MG,</author><journal>World J Gastroenterol</journal><year>2016</year><book /><volume>22</volume><number>36</number><pages>8078-8093</pages><co_aut>et al.</co_aut></literature></Literatures></Disease>